Maternal LSD1/KDM1A is an essential regulator of chromatin and transcription landscapes during zygotic genome activation

  1. Katia Ancelin
  2. Laurène Syx
  3. Maud Borensztein
  4. Noémie Ranisavljevic
  5. Ivaylo Vassilev
  6. Luis Briseño-Roa
  7. Tao Liu
  8. Eric Metzger
  9. Nicolas Servant
  10. Emmanuel Barillot
  11. Chong-Jian Chen
  12. Roland Schüle
  13. Edith Heard  Is a corresponding author
  1. Institut Curie, France
  2. High Fidelity Biology, France
  3. Annoroad Gene Technology Co., Ltd, China
  4. Urologische Klinik und Zentrale Klinische Forschung, Germany

Abstract

Upon fertilization, the highly specialised sperm and oocyte genomes are remodelled to confer totipotency. The mechanisms of the dramatic reprogramming events that occur have remained unknown, and presumed roles of histone modifying enzymes are just starting to be elucidated. Here, we explore the function of the oocyte-inherited pool of a histone H3K4 and K9 demethylase, LSD1/KDM1A during early mouse development. KDM1A deficiency results in developmental arrest by the two-cell stage, accompanied by dramatic and stepwise alterations in H3K9 and H3K4 methylation patterns. At the transcriptional level, the switch of the maternal-to-zygotic transition fails to be induced properly and LINE-1 retrotransposons are not properly silenced. We propose that KDM1A plays critical roles in establishing the correct epigenetic landscape of the zygote upon fertilization, in preserving genome integrity and in initiating new patterns of genome expression that drive early mouse development.

Article and author information

Author details

  1. Katia Ancelin

    Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Laurène Syx

    Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Maud Borensztein

    Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Noémie Ranisavljevic

    Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Ivaylo Vassilev

    Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Luis Briseño-Roa

    High Fidelity Biology, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Tao Liu

    Annoroad Gene Technology Co., Ltd, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Eric Metzger

    Urologische Klinik und Zentrale Klinische Forschung, Freiburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Nicolas Servant

    Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Emmanuel Barillot

    Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Chong-Jian Chen

    Annoroad Gene Technology Co., Ltd, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  12. Roland Schüle

    Urologische Klinik und Zentrale Klinische Forschung, Freiburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. Edith Heard

    Institut Curie, Paris, France
    For correspondence
    Edith.Heard@curie.fr
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: All mice used were handled with care and according to approved institutional animal care and use committee of the Institut Curie (CEEA-IC) protocols(C 75-05-18). The work has also been conducted under the approval from the French Ministry of Higher Education and Research for the use of Genetically Modified Organisms (agreement number 5549CA-I).

Copyright

© 2016, Ancelin et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,494
    views
  • 1,339
    downloads
  • 100
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Katia Ancelin
  2. Laurène Syx
  3. Maud Borensztein
  4. Noémie Ranisavljevic
  5. Ivaylo Vassilev
  6. Luis Briseño-Roa
  7. Tao Liu
  8. Eric Metzger
  9. Nicolas Servant
  10. Emmanuel Barillot
  11. Chong-Jian Chen
  12. Roland Schüle
  13. Edith Heard
(2016)
Maternal LSD1/KDM1A is an essential regulator of chromatin and transcription landscapes during zygotic genome activation
eLife 5:e08851.
https://doi.org/10.7554/eLife.08851

Share this article

https://doi.org/10.7554/eLife.08851

Further reading

    1. Developmental Biology
    2. Neuroscience
    Odessa R Yabut, Jessica Arela ... Samuel J Pleasure
    Research Article

    Mutations in Sonic Hedgehog (SHH) signaling pathway genes, for example, Suppressor of Fused (SUFU), drive granule neuron precursors (GNP) to form medulloblastomas (MBSHH). However, how different molecular lesions in the Shh pathway drive transformation is frequently unclear, and SUFU mutations in the cerebellum seem distinct. In this study, we show that fibroblast growth factor 5 (FGF5) signaling is integral for many infantile MBSHH cases and that FGF5 expression is uniquely upregulated in infantile MBSHH tumors. Similarly, mice lacking SUFU (Sufu-cKO) ectopically express Fgf5 specifically along the secondary fissure where GNPs harbor preneoplastic lesions and show that FGFR signaling is also ectopically activated in this region. Treatment with an FGFR antagonist rescues the severe GNP hyperplasia and restores cerebellar architecture. Thus, direct inhibition of FGF signaling may be a promising and novel therapeutic candidate for infantile MBSHH.

    1. Developmental Biology
    2. Genetics and Genomics
    Svanhild Nornes, Susann Bruche ... Sarah De Val
    Research Article

    The establishment and growth of the arterial endothelium requires the coordinated expression of numerous genes. However, regulation of this process is not yet fully understood. Here, we combined in silico analysis with transgenic mice and zebrafish models to characterize arterial-specific enhancers associated with eight key arterial identity genes (Acvrl1/Alk1, Cxcr4, Cxcl12, Efnb2, Gja4/Cx37, Gja5/Cx40, Nrp1 and Unc5b). Next, to elucidate the regulatory pathways upstream of arterial gene transcription, we investigated the transcription factors binding each arterial enhancer compared to a similar assessment of non-arterial endothelial enhancers. These results found that binding of SOXF and ETS factors was a common occurrence at both arterial and pan-endothelial enhancers, suggesting neither are sufficient to direct arterial specificity. Conversely, FOX motifs independent of ETS motifs were over-represented at arterial enhancers. Further, MEF2 and RBPJ binding was enriched but not ubiquitous at arterial enhancers, potentially linked to specific patterns of behaviour within the arterial endothelium. Lastly, there was no shared or arterial-specific signature for WNT-associated TCF/LEF, TGFβ/BMP-associated SMAD1/5 and SMAD2/3, shear stress-associated KLF4 or venous-enriched NR2F2. This cohort of well characterized and in vivo-verified enhancers can now provide a platform for future studies into the interaction of different transcriptional and signalling pathways with arterial gene expression.